Latest Insider Transactions at Zosano Pharma Corp (ZSANQ)
This section provides a real-time view of insider transactions for Zosano Pharma Corp (ZSANQ). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Zosano Pharma Corp to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Zosano Pharma Corp's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 06
2022
|
Steven Lo Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
442
-3.25%
|
$0
$0.71 P/Share
|
|
Jun 06
2022
|
Christine Matthews Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
82
-1.92%
|
$0
$0.71 P/Share
|
|
Mar 31
2022
|
Steven Lo Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
23,633
-4.88%
|
$0
$0.21 P/Share
|
|
Mar 31
2022
|
Donald J Kellerman VP, Clinical Dev & Med Affairs |
SELL
Open market or private sale
|
Direct |
4,006
-6.64%
|
$0
$0.21 P/Share
|
|
Mar 31
2022
|
Christine Matthews Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
8,116
-5.25%
|
$0
$0.21 P/Share
|
|
Nov 23
2021
|
Kenneth Greathouse Director |
SELL
Open market or private sale
|
Direct |
10,000
-18.69%
|
$0
$0.6 P/Share
|
|
Oct 15
2021
|
Steven Lo Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
118,750
+19.69%
|
-
|
|
Oct 15
2021
|
Christine Matthews Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
56,250
+26.69%
|
-
|
|
Oct 15
2021
|
Donald J Kellerman VP, Clinical Dev & Med Affairs |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+14.22%
|
-
|
|
Jun 10
2021
|
Joseph P Hagan Director |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+40.0%
|
-
|
|
Jun 10
2021
|
Kleanthis G Xanthopoulos Director |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+38.86%
|
-
|
|
Jun 10
2021
|
Kenneth Greathouse Director |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+21.9%
|
-
|
|
Jun 10
2021
|
Steve Elms Director |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+40.0%
|
-
|
|
Jun 10
2021
|
Linda Grais Director |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+40.0%
|
-
|
|
Jun 04
2021
|
Christine Matthews Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,709
-1.71%
|
$0
$0.8 P/Share
|
|
Jun 04
2021
|
Donald J Kellerman VP, Clinical Dev & Med Affairs |
SELL
Open market or private sale
|
Direct |
1,709
-3.28%
|
$0
$0.8 P/Share
|
|
Jun 04
2021
|
Hayley Lewis Officer |
SELL
Open market or private sale
|
Direct |
1,709
-3.32%
|
$0
$0.8 P/Share
|
|
Jun 04
2021
|
Steven Lo Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
13,158
-3.47%
|
$0
$0.8 P/Share
|
|
May 17
2021
|
Kenneth Greathouse Director |
BUY
Grant, award, or other acquisition
|
Direct |
21,000
+35.29%
|
$0
$0.73 P/Share
|
|
Mar 30
2021
|
Christine Matthews Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
81,250
+44.83%
|
-
|
|
Mar 30
2021
|
Donald J Kellerman VP, Clinical Dev & Med Affairs |
BUY
Grant, award, or other acquisition
|
Direct |
32,500
+38.44%
|
-
|
|
Mar 30
2021
|
Hayley Lewis Officer |
BUY
Grant, award, or other acquisition
|
Direct |
32,500
+38.7%
|
-
|
|
Mar 30
2021
|
Steven Lo Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
232,500
+38.04%
|
-
|